Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia

Children's Oncology Group

Status: Completed

Conditions: Leukemia

Treatments: Other: laboratory biomarker analysis; Other: cell culture procedure

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01139307

CDR0000671427 (Other Identifier)

COG-AAML10B1 (Other Identifier)

AAML10B1

NCI-2011-02218 (Registry Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.

Full description

OBJECTIVES:

• Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia.

OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.

Enrollment: 10 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of acute megakaryoblastic leukemia
• Diagnosis of Down syndrome
• Cryopreserved specimens available

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified